Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Trospium Cation
2. 47608-32-2
3. Trospium Ion
4. T4y8ork057
5. [(1s,5r)-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-azolidin-1-ium]-3-yl] 2-hydroxy-2,2-diphenylacetate
6. Ncgc00167438-01
7. Ncgc00167438-02
8. Unii-t4y8ork057
9. Tropsium Cation
10. Tropsium Ion
11. Trospium [vandf]
12. Trospium [who-dd]
13. Schembl119810
14. Schembl2447242
15. Chembl1888176
16. Chebi:145791
17. Zinc12503068
18. 3alpha-hydroxyspiro(1alphah,5alphah-nortropane-8,1'-pyrrolidinium) Benzilate
19. Zinc100016084
20. Zinc100371992
21. Am84314
22. Db00209
23. Ab01274814-01
24. Ab01274814_02
25. 3.alpha.-hydroxyspiro(1.alpha.h,5.alpha.h-nortropane-8,1'-pyrrolidinium) Benzilate
26. (1alpha,3beta,5alpha)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium]
27. (1alpha,5alpha)-3beta-[(hydroxydiphenylacetyl)oxy]spiro[8-azoniabicyclo[3.2.1]octane-8,1'-pyrrolidinium]
28. (1s,3r,5r)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-8lambda(5)-azaspiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-8-ylium
29. Spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium), 3-((hydroxydiphenylacetyl)oxy)-, (1.alpha.,3.beta.,5.alpha.)-
| Molecular Weight | 392.5 g/mol |
|---|---|
| Molecular Formula | C25H30NO3+ |
| XLogP3 | 4.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 5 |
| Exact Mass | 392.22256882 g/mol |
| Monoisotopic Mass | 392.22256882 g/mol |
| Topological Polar Surface Area | 46.5 Ų |
| Heavy Atom Count | 29 |
| Formal Charge | 1 |
| Complexity | 553 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.
FDA Label
Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. According to receptor assays, it displays higher affinity towards muscarininc receptors compared to nicotinic receptors at therapeutic concentrations.
G04BD09
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
G - Genito urinary system and sex hormones
G04 - Urologicals
G04B - Urologicals
G04BD - Drugs for urinary frequency and incontinence
G04BD09 - Trospium
Absorption
9.6%
Route of Elimination
After administration of oral 14C-trospium chloride, the majority of the dose (85.2%) was recovered in feces and a smaller amount (5.8% of the dose) was recovered in urine; 60% of the radioactivity excreted in urine was unchanged trospium. Trospium mainly undergoes elimination via active tubular secretion, as indicated by the mean renal clearance of 29.07 L/hour, which is about 4-fold higher than average glomerular filtration rate. Trospium is metabolized by ester hydrolysis and excreted by the kidneys by a combination of tubular secretion and glomerular filtration.
Volume of Distribution
395 140 L
Clearance
Renal cl=29.07 L/hour
Not fully defined
20 hours
Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Trospium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Trospium, including repackagers and relabelers. The FDA regulates Trospium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Trospium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Trospium supplier is an individual or a company that provides Trospium active pharmaceutical ingredient (API) or Trospium finished formulations upon request. The Trospium suppliers may include Trospium API manufacturers, exporters, distributors and traders.
Trospium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Trospium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Trospium GMP manufacturer or Trospium GMP API supplier for your needs.
A Trospium CoA (Certificate of Analysis) is a formal document that attests to Trospium's compliance with Trospium specifications and serves as a tool for batch-level quality control.
Trospium CoA mostly includes findings from lab analyses of a specific batch. For each Trospium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Trospium may be tested according to a variety of international standards, such as European Pharmacopoeia (Trospium EP), Trospium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Trospium USP).
LOOKING FOR A SUPPLIER?
